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June 2014 using SAS version 9.2 (SAS Institute, Inc, Cary, NC). The details of the methodology are described in the online-only Data Supplement.
Results
Among the 535 patients, 295 (55.1%) were not prescribed a statin, 125 (23.4%) were prescribed a low-potency statin, and 115 (21.5%) were prescribed a high-potency statin. The mean duration of follow-up was 22.2 (median, 17.4; interquartile range, 8.0-34.1) months. Baseline characteristics are described (Table II in the online-only Data Supplement). Forty-two patients died (35 from the nonstatin group, 5 from the low-potency group, and 2 from the high-potency group): 11 from cardiac disease, 11 from recurrent stroke, 13 from other causes (including infection and cancer), and 7 from unknown causes. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. With regard to recurrent stroke, 40 patients had a recurrence (29 from the nonstatin group, 12 from the low-potency group, and 7 from the high-potency group) during follow-up. The cumulative proportion of patients with recurrent stroke was 5% at the end of the first year and 13% at the end of the third year.
In patients with cardioembolic stroke, statin therapy was independently associated with reduced mortality (Table) . Kaplan-Meier estimation shows that either low-or highpotency statin therapy was associated with reduced mortality (log-rank test; P=0.006; Figure) . There was no difference in survival between the low-and high-potency statin groups. The relative benefit in terms of mortality of statin therapy showed no heterogeneity according to the demographic, clinical, or laboratory risk factors in subgroup analyses ( Figure II in the online-only Data Supplement). However, statin therapy did not show a significant benefit in stroke recurrence (Table III in the online-only Data Supplement).
The beneficial effect of statin therapy for patients with noncardioembolic stroke was similar to the effect in patients with cardioembolic stroke (Table IV in the online-only Data Supplement). Statin therapy significantly reduced mortality in patients with noncardioembolic stroke. The interaction between cardioembolic and noncardioembolic stroke 
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Statins' Benefit in Cardioembolic Stroke 3 about the benefit of statins on mortality was not significant (P=0.099). However, the beneficial effect of statin therapy on recurrent stroke was also not observed in patients with noncardioembolic stroke.
Discussion
Various aspects of the beneficial effect of statin therapy in patients with previous stroke have been previously reported. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study showed a 16% relative risk reduction of fatal or nonfatal stroke. Statin therapy was also associated with a reduction in major cardiovascular accidents. 1 Subgroup analysis of the Heart Protection Study (HPS) showed statin-induced risk reduction in major coronary and vascular events in patients with previous stroke. 2 Results from both studies suggest that patients with a previous stroke may benefit from statins via prevention of stroke and other major vascular events. However, it should be noted that patients in both studies were primarily at risk of atherosclerotic carotid or coronary vascular disease. In the SPARCL trial, patients with a major source of cardioembolic stroke (AF, valvular heart disease, and coronary artery disease [CAD]) were excluded. 1 Information about the prevalence of cardiac arrhythmia was not reported in the HPS.
2 Several registry-based observational studies have also shown a beneficial effect of statin therapy on stroke recurrence, mortality, and functional outcome in patients with acute ischemic stroke. 7, 8 However, these studies included patients with all stroke subtypes. As a consequence, it was not clear whether the patients with cardioembolic stroke without known CAD should be treated with a statin. Therefore, the results from the present study may shed light on this question.
In the present study, the effect of statins on mortality did not change according to the potency of the statin, although high-potency statins seemed to be superior. In addition, the effect was not restricted to patient age, total and low-density lipoprotein cholesterol levels, inflammatory condition (C-reactive protein level and white blood cell count), stroke severity (National Institutes of Health Stroke Scale score), anticoagulation therapy, or other previously known cardiovascular risk factors, including hypertension, diabetes mellitus, CAD, and cerebral atherosclerosis. It should be noted, when interpreting our results, that the levels of total and low-density lipoprotein cholesterol and the prevalence of concomitant CAD and cerebral atherosclerosis were lower in patients in the nonstatin group (Table II in the onlineonly Data Supplement). In other words, patients in the statin group were at greater risk for adverse vascular complications compared with patients who were not treated with statins. It may seem paradoxical that patients at high risk have better outcomes, considering the current guideline for use in the secondary prevention of stroke. 9 Therefore, the results of the present study suggest that statin therapy has additional benefits beyond its current indications.
There are several aspects of the beneficial effect of statins in the present study that should be considered. Although AF was the most common source of cardioembolism in the present study, epidemiological studies have shown that patients with AF are more likely to have diabetes mellitus, hypertension, myocardial infarction, and congestive heart failure. 3 Importantly, AF has been known to be a risk factor for CAD, 10 and the major cause of death in patients with AF is CAD. 11 Besides AF, ≈12% of cardioembolic strokes in this study were atherosclerotic in origin, and most of them were from an aortic complex atheroma (Table I in the online-only Data Supplement). However, the prevalence of complex aortic plaques may be higher, considering that complex aortic plaques were reported in ≈25% of patients with AF 12 and the underperformance of transesophageal echocardiography in patients with stroke with documented AF. Therefore, the effect of statins on concomitant CAD and aortic complex atheroma 13 via modifying lipid metabolism and increasing plaque stabilization mechanisms may be linked to the reduced mortality seen in the present study. Otherwise, the neuroprotective and anti-inflammatory (pleiotropic) effects of statins may also partially have a beneficial effect on mortality.
Stroke recurrence was not different among the groups of cardioembolic stroke in the present study. As a matter of fact, statins may not reduce stroke recurrence in cardioembolic infarction. Although antiplatelet effects of statins have been documented, 14 recurrence of stroke in patients with cardioembolic stroke is mostly attributed to AF and is only effectively prevented by anticoagulation. 15 This study has some limitations. Because of the retrospective study design, we could not exclude the presence of undetected bias. Furthermore, prescription of statins might not occur in patients with severe neurological deficits (selection bias). However, we attempted to minimize bias by adjusting all obtainable demographic and clinical data. Subgroup
Stroke
June 2014
analyses also reconfirmed the effect of statins on mortality. Despite these limitations, our study showed a potential benefit of statin therapy in patients with cardioembolic stroke. Large, randomized, controlled studies should be performed to confirm the effect of statins on cardioembolic stroke. 
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I. Korea University Stroke Registry (KUSR)
The KUSR collects demographic, clinical, radiological, and laboratory data from acute stroke patients within seven days from the onset of symptoms. Three tertiary medical centers contribute to KUSR, including Korea University Anam Hospital in the northern part of Seoul, Korea University
Guro Hospital in the southern part of Seoul, and Korea University Ansan Hospital in the southeastern part of the Gyeonggi province.
Stroke diagnosis was based on the criteria of focal neurological deficit with relevant lesions on brain images. Patients whose symptoms lasted less than 24 hours were diagnosed as having stroke if relevant lesions were found on brain imaging. Vascular risk factors assessed in this study included hypertension, diabetes mellitus (DM), smoking, congestive heart failure (CHF), and CAD. CAD was defined as having a history of any of the following at admission: stable angina pectoris, acute coronary syndrome, coronary revascularization, or acute myocardial infarction. Cerebral atherosclerosis was defined by any significant stenosis (>50% in diameter reduction) in intracranial or extracranial cerebral arteries found on CT angiography, MR angiography, or conventional catheter-based angiography. Laboratory data were tested at the date of admission or the next day after at least eight hours of fasting, and included white blood cell count (WBC), fasting glucose, total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, C-reactive protein (CRP), and fibrinogen. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS). All patients were classified into five groups according to the TOAST classification at the time of discharge. 1 The treatment protocols in our three university hospitals generally follow the major guidelines for stroke management. 2, 3 Specifically, statin therapy was initiated immediately after risk stratification, and a stroke physician decided the dosage and type of statin based on the patients' conditions.
II. Non-cardioembolic stroke cohort
To compare the effect of statins according to the stroke subtype, we initially recruited 2507 subjects with first ever non-cardioembolic stroke during the study period. Among them, 226 patients were lost to follow-up within 30 days from discharge, 159 were excluded due to an incomplete dataset, and 6 were excluded due to early mortality. Therefore 2116 subjects with non-cardioembolic stroke were finally included. The non-cardioembolic stroke group was subdivided into a non-statin group (n = 806) and a statin therapy group (n = 1310). A schematic of the study design is illustrated ( Figure 1 in the online-only Data Supplement).
III. Outcome Assessment
The primary outcomes in this study were time to recurrent stroke and time to mortality due to any cause. Data regarding patient outcomes were obtained via regular outpatient visits with the subjects or from family members. Additionally, a trained interviewer conducted telephone interviews with patients who were unable to visit the outpatient clinics. Recurrent stroke was defined by symptoms correlating with lesions on brain imaging, and included both ischemic and hemorrhagic stroke. The cause of mortality was divided into four categories. Cardiac-related death was defined when the patients died of sudden cardiac arrest or myocardial infarction. Stroke-related death was defined when the patients died of brain herniation or brain-death caused by recurrent ischemic or hemorrhagic stroke. Other cause of death was defined when the patients died due to cancer or infection, whether or not the infection occurred with a stroke-related complication. An unknown cause of death was defined when the mortality information was obtained via telephone-interview.
IV. Statistical analyses
All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Car, N.C., USA).
First, the baseline characteristics of the cardioembolic stroke cohort were analyzed. Continuous variables were presented as mean and standard deviation (SD) or median and interquartile range, according to the distribution of the variables. Categorical variables were presented as number and percentage. Second, the effects of statin therapy on mortality and recurrent stroke in patients with cardioembolic stroke were analyzed using univariable/multivariable Cox proportional hazard models and Kaplan-Meier analyses. Third, subgroup analyses among the cardioembolic stroke were performed with p-values for the main effect (an equality of magnitude of HR) as well as for the interactions (equality of HR directionalities). Finally, the effect of statin therapy for cardioembolic stroke was compared with those for non-cardioembolic stroke using univariable/multivariable Cox proportional hazard models with interaction analyses.
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Figure I Flow diagram of patient inclusion
Figure II Effects of statin on mortality according to baseline characteristics in the cardioembolic stroke cohort 
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